ATE517120T1 - Igf-1 fusion polypeptide und deren therapeutische verwendung - Google Patents

Igf-1 fusion polypeptide und deren therapeutische verwendung

Info

Publication number
ATE517120T1
ATE517120T1 AT06717668T AT06717668T ATE517120T1 AT E517120 T1 ATE517120 T1 AT E517120T1 AT 06717668 T AT06717668 T AT 06717668T AT 06717668 T AT06717668 T AT 06717668T AT E517120 T1 ATE517120 T1 AT E517120T1
Authority
AT
Austria
Prior art keywords
igf1
component
igf
fusion
therapeutic use
Prior art date
Application number
AT06717668T
Other languages
English (en)
Inventor
David Glass
George Yancopoulos
Thomas Daly
Nicholas Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE517120T1 publication Critical patent/ATE517120T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
AT06717668T 2005-01-07 2006-01-06 Igf-1 fusion polypeptide und deren therapeutische verwendung ATE517120T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64222905P 2005-01-07 2005-01-07
US65658305P 2005-02-25 2005-02-25
PCT/US2006/000495 WO2006074390A2 (en) 2005-01-07 2006-01-06 Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides

Publications (1)

Publication Number Publication Date
ATE517120T1 true ATE517120T1 (de) 2011-08-15

Family

ID=42634965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717668T ATE517120T1 (de) 2005-01-07 2006-01-06 Igf-1 fusion polypeptide und deren therapeutische verwendung

Country Status (12)

Country Link
US (4) US7396918B2 (de)
EP (2) EP1833847B1 (de)
JP (1) JP4988599B2 (de)
AT (1) ATE517120T1 (de)
AU (1) AU2006203882B2 (de)
CA (1) CA2594023C (de)
DK (1) DK2241575T3 (de)
ES (1) ES2541810T3 (de)
HU (1) HUE027645T2 (de)
PL (2) PL2241575T3 (de)
PT (1) PT2241575E (de)
WO (1) WO2006074390A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521211B2 (en) 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
BRPI0715754A2 (pt) * 2006-08-31 2013-07-09 Hoffmann La Roche mÉtodo para a produÇço de fator do crescimento similar Á insulina i
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
GB0715213D0 (en) * 2007-08-06 2007-09-12 Asterlon Ltd Igf-1
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2010088502A2 (en) * 2009-01-30 2010-08-05 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
US7963705B2 (en) * 2009-02-24 2011-06-21 Avago Technologies Fiber Ip (Singapore) Pte. Ltd. Molded interconnect device (MID) optical connector with metal retaining clip
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
CN102618575A (zh) * 2011-09-16 2012-08-01 江苏普罗赛生物技术有限公司 哺乳动物细胞大规模生产重组人IGF1-Fc融合蛋白的实验技术
SG11201503782PA (en) * 2012-12-18 2015-06-29 Novartis Ag Stabilized insulin-like growth factor polypeptides
EP2935319B1 (de) * 2012-12-18 2019-04-24 Novartis AG Herstellung von therapeutischen proteinen in genetisch veränderten säugetierzellen
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
JP2016535080A (ja) 2013-10-02 2016-11-10 ノバルティス アーゲー 療法における使用のためのインスリン様成長因子模倣物
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
EP3100056A2 (de) 2014-01-27 2016-12-07 Novartis AG Biomarker zur prädiktion von muskelatrophie, verfahren und verwendung
WO2016115171A1 (en) * 2015-01-16 2016-07-21 The Regents Of The University Of California Insulin-like growth factor 2 (igf2) signaling and modulation
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
KR102646323B1 (ko) * 2016-05-06 2024-03-13 이뮤노포지 주식회사 제어된 지속 방출을 위한 elp 융합 단백질
WO2018189661A2 (en) * 2017-04-10 2018-10-18 Palti Yoram Prof Methods and compounds for treating diabetes
EP3453722A1 (de) * 2017-09-06 2019-03-13 Julius-Maximilians-Universität Würzburg Pharmazeutika und vorrichtungen für kovalente immobilisierung an der extrazellulären matrix durch transglutaminase
CN113214410A (zh) * 2017-11-04 2021-08-06 海南大学 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法
EP3569614A1 (de) * 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
EP4606428A3 (de) * 2018-06-27 2025-11-05 Juvena Therapeutics, Inc. Heparin-assoziierte polypeptide und deren verwendungen
JP2022552254A (ja) * 2019-10-10 2022-12-15 アミカス セラピューティックス インコーポレイテッド バリアントｉｇｆ２構築体
EP4081241A4 (de) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. Regenerative polypeptide und verwendungen dafür
CA3198225A1 (en) * 2020-10-13 2022-04-21 Betavive Ltd. Method and compounds for treating diabetes and associated metabolic diseases
EP4359425B1 (de) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2-fusionspolypeptid und verwendung bei der behandlung von muskeldystrophie, sarkopenie, kachexie oder muskelverletzungen
WO2023062545A1 (en) 2021-10-12 2023-04-20 Betavive Ltd. Peptides and fragments for treating diabetes and associated metabolic diseases
KR20230156889A (ko) * 2022-05-04 2023-11-15 이뮤노포지 주식회사 GLP-1, 면역글로불린 Fc, 및 IGF-1을 포함하는 융합단백질 및 이의 용도
GB202216503D0 (en) * 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA2033176C (en) * 1989-06-09 1999-12-14 Julian Richard Este Wells Growth hormone fusion proteins
US5473051A (en) * 1990-07-19 1995-12-05 The Scripps Research Institute Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
EP0639981A4 (de) * 1992-05-08 1995-06-28 Univ Jefferson Analoge des igf-faktors(18.01.94).
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6413740B1 (en) 1995-12-15 2002-07-02 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
AUPP298498A0 (en) 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
CN101873809B (zh) 2007-07-23 2014-11-12 R.J.雷诺兹烟草公司 无烟烟草组合物

Also Published As

Publication number Publication date
WO2006074390A3 (en) 2007-01-11
DK2241575T3 (en) 2015-08-24
HK1144684A1 (en) 2011-03-04
AU2006203882B2 (en) 2011-05-12
JP2008526233A (ja) 2008-07-24
CA2594023C (en) 2015-07-14
PL1833847T3 (pl) 2011-12-30
EP2241575B1 (de) 2015-06-24
PT2241575E (pt) 2015-09-16
WO2006074390A2 (en) 2006-07-13
US20090069235A1 (en) 2009-03-12
AU2006203882A1 (en) 2006-07-13
US20060166328A1 (en) 2006-07-27
EP1833847B1 (de) 2011-07-20
US8445434B2 (en) 2013-05-21
CA2594023A1 (en) 2006-07-13
US20110020342A1 (en) 2011-01-27
EP1833847A2 (de) 2007-09-19
US7837999B2 (en) 2010-11-23
US20120195896A1 (en) 2012-08-02
US8158581B2 (en) 2012-04-17
PL2241575T3 (pl) 2015-12-31
US7396918B2 (en) 2008-07-08
ES2541810T3 (es) 2015-07-24
JP4988599B2 (ja) 2012-08-01
HUE027645T2 (en) 2016-10-28
EP2241575A1 (de) 2010-10-20

Similar Documents

Publication Publication Date Title
PT2241575E (pt) Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos
DE602005016917D1 (de) Fgf-21-fusionsproteine
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
LTC1641823I2 (lt) GLP-1 analogo sulieti baltymai
DE602004013372D1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
DE60135581D1 (de) Glp-1 fusion proteine
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
DK1005488T4 (da) Receptor som binder TRAIL
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DE59914490D1 (de) Ein faktor viii-polypeptid mit faktor viii:c-aktivität
WO2007064919A3 (en) Binding polypeptides with restricted diversity sequences
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
ATE541935T1 (de) Wachstumshormon fusionprotein
ATE471956T1 (de) Verzweigte polyalkylenglykole
ATE493432T1 (de) Gewinnung von hitzeschockproteinen
WO2005069726A3 (en) Hybrid and chimeric polypeptides that regulate activation of complement
ATE466880T1 (de) Cytokinpolypeptidvarianten
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
IL165776A0 (en) Methods and compositions for modulating and detecting wisp activity
EP1497307A4 (de) Impfstoff mit rekombinantem p.falciparum-merozoitprotein-1 42

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1833847

Country of ref document: EP